Co-crystal of dapagliflozin with citric acid
US9676741B1 · kind B1 · utility
7Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 2015 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Jun 23, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to a dapagliflozin-citric acid co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus. A dapagliflozin citric acid co-crystal. The dapagliflozin citric acid co-crystal of claim 1, characterized by X-ray powder diffraction peaks having d-spacing values at about 3.89, 3.90, 4.01, 4.35, 5.77, and 5.80.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.